Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The era of anti-cytokine treatment in rheumatology has just begun. The first generation therapeutic agents, biological agents that block tumour necrosis factor alpha such as monoclonal antibodies or receptor Ig fusion proteins are safe and effective, and so this has generated much interest in how to increase the benefit or deliver it more cost effectively. This article provides a personal view of the coming trends in anti-cytokine treatment. Which of these will be realised in the future will be of interest.

Original publication

DOI

10.1136/ard.59.suppl_1.i119

Type

Journal article

Journal

Ann Rheum Dis

Publication Date

11/2000

Volume

59 Suppl 1

Pages

i119 - i122

Keywords

Antirheumatic Agents, Arthritis, Rheumatoid, Cytokines, Forecasting, Humans